These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32886262)

  • 1. T cell receptor repertoires of ex vivo-expanded tumor-infiltrating lymphocytes from breast cancer patients.
    Park IA; Rajaei H; Kim YA; Lee H; Lee H; Seo JH; Heo SH; Song IH; Gong G; Lee HJ
    Immunol Res; 2020 Oct; 68(5):233-245. PubMed ID: 32886262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
    Ham B; Kim SY; Kim YA; Han D; Park T; Cha S; Jung S; Kim JH; Park G; Gong G; Lee HJ; Shin J
    Br J Cancer; 2024 Jul; 131(1):196-204. PubMed ID: 38750113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
    Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
    Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.
    Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T; Saito S; Fujii T; Muraguchi A; Shiku H; Kishi H
    Eur J Immunol; 2020 Oct; 50(10):1580-1590. PubMed ID: 32441316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant Expression of CD39, CD69, and CD103 Identifies Antitumor CD8
    Lama GIG; Noél G; Márquez FCL; Galarza FFG; Hinojosa AIP; Rivera LEN; Willard-Gallo K; Astorga JRA
    Curr Pharm Biotechnol; 2024; 25(13):1747-1757. PubMed ID: 37680154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
    Gros A; Robbins PF; Yao X; Li YF; Turcotte S; Tran E; Wunderlich JR; Mixon A; Farid S; Dudley ME; Hanada K; Almeida JR; Darko S; Douek DC; Yang JC; Rosenberg SA
    J Clin Invest; 2014 May; 124(5):2246-59. PubMed ID: 24667641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines.
    Nishimura MI; Kawakami Y; Charmley P; O'Neil B; Shilyansky J; Yannelli JR; Rosenberg SA; Hood L
    J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):85-94. PubMed ID: 7804531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
    Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
    Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
    Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
    J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.
    Zeppellini A; Galimberti S; Leone BE; Pacifico C; Riva F; Cicchiello F; Capici S; Maggioni C; Sala L; Cazzaniga ME
    BMC Cancer; 2021 Mar; 21(1):260. PubMed ID: 33691674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the T-cell receptor beta chain repertoire in tumor-infiltrating lymphocytes.
    Nakanishi K; Kukita Y; Segawa H; Inoue N; Ohue M; Kato K
    Cancer Med; 2016 Sep; 5(9):2513-21. PubMed ID: 27465739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous expansion of CD4+ tumor-infiltrating T-lymphocytes in clear cell renal cell carcinomas.
    Zhang Q; Jia Q; Deng T; Song B; Li L
    Biochem Biophys Res Commun; 2015 Feb; 458(1):70-6. PubMed ID: 25637538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor α and β Repertoires.
    Gil A; Kamga L; Chirravuri-Venkata R; Aslan N; Clark F; Ghersi D; Luzuriaga K; Selin LK
    mBio; 2020 Mar; 11(2):. PubMed ID: 32184241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response.
    Aran A; Lázaro G; Marco V; Molina E; Abancó F; Peg V; Gión M; Garrigós L; Pérez-García J; Cortés J; Martí M
    Front Immunol; 2023; 14():1227766. PubMed ID: 37600765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAV gene expression in PBMCs and TILs in patients with breast cancer analyzed by a DNA melting curve (FQ-PCR) technique for TCR α chain CDR3 spectratyping.
    He XY; Yang WM; Tang WT; Ma R; Sun YP; Wang P; Yao XS
    Neoplasma; 2012; 59(6):693-9. PubMed ID: 22862170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer.
    Goto R; Hirota Y; Aruga T; Horiguchi S; Miura S; Nakamura S; Takimoto M
    Breast Cancer; 2020 Jul; 27(4):586-593. PubMed ID: 31933123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models.
    Morello G; Cancila V; La Rosa M; Germano G; Lecis D; Amodio V; Zanardi F; Iannelli F; Greco D; La Paglia L; Fiannaca A; Urso AM; Graziano G; Ferrari F; Pupa SM; Sangaletti S; Chiodoni C; Pruneri G; Bardelli A; Colombo MP; Tripodo C
    Cancer Immunol Res; 2021 Jul; 9(7):825-837. PubMed ID: 33941587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.
    Page DB; Yuan J; Redmond D; Wen YH; Durack JC; Emerson R; Solomon S; Dong Z; Wong P; Comstock C; Diab A; Sung J; Maybody M; Morris E; Brogi E; Morrow M; Sacchini V; Elemento O; Robins H; Patil S; Allison JP; Wolchok JD; Hudis C; Norton L; McArthur HL
    Cancer Immunol Res; 2016 Oct; 4(10):835-844. PubMed ID: 27587469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.